Ocrevus Zunovo Interactions
There are 508 drugs known to interact with Ocrevus Zunovo (hyaluronidase/ocrelizumab), along with 4 disease interactions. Of the total drug interactions, 44 are major, 387 are moderate, and 77 are minor.
- View all 508 medications that may interact with Ocrevus Zunovo
- View Ocrevus Zunovo disease interactions (4)
Most frequently checked interactions
View interaction reports for Ocrevus Zunovo (hyaluronidase / ocrelizumab) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- albuterol
- albuterol / ipratropium
- alendronate
- ambrisentan
- amitriptyline
- amlodipine
- Amondys 45 (casimersen)
- apple cider vinegar
- apremilast
- Aspirin Low Strength (aspirin)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- azelastine nasal
- Azo Urinary Pain Relief (phenazopyridine)
- baclofen
- Bafiertam (monomethyl fumarate)
- Benadryl (diphenhydramine)
- Benlysta (belimumab)
- betamethasone topical
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blincyto (blinatumomab)
- Eliquis (apixaban)
- Ocrevus (ocrelizumab)
Ocrevus Zunovo disease interactions
There are 4 disease interactions with Ocrevus Zunovo (hyaluronidase / ocrelizumab) which include:
Report options
QR code containing a link to this page
More about Ocrevus Zunovo (hyaluronidase / ocrelizumab)
- Ocrevus Zunovo consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
